WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

A BREAKTHROUGH HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

Globally, an estimated 4,000 adolescent girls and young women become infected with HIV each week, with sub-Saharan Africa accounting for more than 60% of these new infections, according to the World ...

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.Presented ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...

Newsday Zimbabwe HEALTH and Child Care minister Douglas Mombeshora has reaffirmed the country’s commitment to advancing HIV research, treatment and global collaboration. He said this during the ...

As borders tighten, Global South citizens say they are being locked out of high-level talks that impact them the most.

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s ...

Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...